Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

1. VERU stock drops 48.5% after Phase 2b study results. 2. Enobosarm showed significant lean mass preservation compared to Wegovy alone. 3. Patients using enobosarm lost 71% less lean mass than those on Wegovy. 4. Major differences in fat loss favor enobosarm patients over placebo group. 5. Safety data remains blind; full results expected by April 2025.